Combination bacteriolytic therapy for the treatment of tumors

Details Combination bacteriolytic therapy for the treatment of tumors Combination bacteriolytic therapy for the treatment of tumors

2002-11-21

2008-03-18

Navarro, Mark (Department: 1645)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

C424S093200, C424S093410

Reexamination Certificate

active

07344710

ABSTRACT:
Current chemotherapeutic approaches for cancer are in part limited by the inability of drugs to destroy neoplastic cells within poorly vascularized compartments of tumors. We have here systematically assessed anaerobic bacteria for their capacity to grow expansively within avascutar compartments of transplanted tumors. Among 26 different strains tested, one (Clostridium novyi) appeared particularly promising. We created a strain ofC. novyidevoid of its lethal toxin (C. novyi-NT) and showed that intravenously injectedC. novyi-NT spores germinated within the avascular regions of tumors in mice and destroyed surrounding viable tumor cells. WhenC. novyi-NT spores were administered together with conventional chemotherapeutic drugs, extensive hemorrhagic necrosis of tumors often developed within 24 hours, resulting in significant and prolonged anti-tumor effects. This strategy, called combination bacteriolytic therapy (COBALT), has the potential to add a valuablle dimension to the treatment of cancer.

REFERENCES:
Brown, Martin J. et al., “The Unique Physiology of Solid Tumors: Opportunities (and Problems) for Cancer Therapy,”Cancer Research(Apr. 1, 1998), pp. 1408-1416, vol. 58.
Cary, R.W. et al., “Clostridial Oncolysis in Man,”Europ. J. Cancer(1987) pp. 37-46, vol. 3.
Clairmont, C. et al. “Biodistribution and Genetic Stability of the Novel Antitumor Agent VNP20009, a Genetically Modified Strain ofSalmonella typhimuriumj,” (2000), pp. 1996-2002, vol. 181.
Dang, Long H. et al., “Combination bacteriolytic therapy for the treatment of experimental tumors,” www.pnas.org/cgi/dol/10,1073/pnas.251543698, Nov. 27, 2001.
Gericke, Dietmar et al., “Oncolysis by Clostridia. II. Experiments on a Tumor Spectrum with a Variety of Clostridia in Combination with Heavy Metals,”Cancer Research, (Feb. 1964), pp. 217-221, vol. 24.
Kimura, Noritaka T. et al., “Selective Localization and Growth ofBifidobacterium bifidumin Mouse Tumors following Intravenous Administration,”Cancer Research, (Jun. 1980), pp. 2061-2068, vol. 40.
Kohwi, Yoshinori et al., “Antitumor Effect ofBifidobacterium infantisin Mice,”Gann, (Oct. 1978), pp. 613-618.
Lemmon, MJ et al., “Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment,”Gene Therapy, (1997), pp. 791-796, vol. 4.
Low, K. Brooks et al., “Lipid A mutantSalmonellawith suppressed virulence and TNFα induction retain tumor-targeting in vivo,”Nature Biotechnology,(Jan. 1999) pp. 37-41, vol. 17.
Malmgren, Richard A. et al. Localization of the Vegetative Form ofClostridium tetaniin Mouse Tumors Following Intravenous Spore Administration,Cancer Research,(1995), pp. 473-478.
Mose, J.R. et al., “Oncolysis by Clostridia. I. Activity ofClostridium butyricum(M-55) and Other Nonpathogenic Clostridia against the Ehrlich Carcinoma,”Cancer Research, (Feb. 1964), pp. 212-216, vol. 24.
Parker, Raymond C. et al., “Effect of Histolyicus Infection and Toxin on Transplantable Mouse Tumors,”Proc. Soc. Exp. Biol. Med., (1947), pp. 461-467.
Schmassman, Adrian et al., “Cholecystokinin-B/gastrin receptors enhance wound healing in the rat gastric mucosa,”J. Clin. Invest., (Oct. 2000), pp. 1021-1029, vol. 106, No. 8.
Yazawa, Kazuyuki et al., “Bifidobacterium longumas a delivery system for gene therapy of chemically induced rat mammary tumors,”Breast Cancer Research and Treatment, (2001), pp. 165-170, vol. 66.
Jeha S., “Tumor lysis syndrome,”Semin Hematol,Oct. 2001; 38(4, Suppl 10):4-8 (Abstract only).
Martinez RD et al., Comparison of Clostridium sordellil toxins and LT with toxins A and B of C. difficile.,J Med Microbiol,Jan. 1992; 36(1):30-6 (Abstract only).
Dang, Long H. Combination bacteriolytic therapy for the treatment of experimental tumors. Proceedings of the National Academy of Science. Dec. 18, 2001, vol. 98, No. 26, pp. 15155-15160, see entire document.
Eklund M W et al: “Relationship of bacteriophages to alpha toxin production in Clostridium novyi types A and B.” Infection and Immunity. Sep. 1976, vol. 14, No. 3, pp. 793-803, XP002405800 ISSN: 0019-9567.
Eklund M W et al: “Interspecies conversion of clostridium botulinum type C to clostridium novyi type A by bacteriophage” SCIENCE 1974, vol. 186, No. 4162, 1974, pp. 456-458, XP002405801.
Minton N P et al: “Chemotherapeutic tumour targeting using clostridial spores” FEMS Microbiology Reviews, Elsevier, Amsterdam, NL, vol. 17, No. 3, 1995, pp. 357-364, XP002242524 ISSN: 0168-6445.
Minton N P et al: “Clostridia in Cancer Therapy” In: Bahl H and Dürre P Editors, Clostridia-Biotechnology and Medical Applications, Wiley-VCH, Weinheim, ISBN 3-527-30175-5, Feb. 15, 2001, pp. 251-270, XP001247867.
Theys J et al: “Improvement of Clostridium Tumour Tergetting Vectors Evaluated in Rat Rhabdomyosarcomas” FEMS Immunology and Medical Microbiology, Elsevier Science B.V., Amsterdam, NL, vol. 30, No. 1, Feb. 2001, pp. 37-41, XP001097591 ISSN: 0928-8244.
Hatheway C L: “Toxigenic clostridia.”Clinical Microbiology Reviews. Jan. 1990, vol. 3, No. 1, 1, Jan. 1990, pp. 66-98, XP002408674 ISSN: 0893-8512.

Affiliated with

Also associated with

Rating

Combination bacteriolytic therapy for the treatment of tumors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Combination bacteriolytic therapy for the treatment of tumors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination bacteriolytic therapy for the treatment of tumors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3961467